Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$16.92 USD

16.92
1,422,417

-0.30 (-1.74%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $16.90 -0.02 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Hold on to Ecolab (ECL) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Zacks Equity Research

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.

Zacks Equity Research

Charles River (CRL) to Create New Gene Therapy for Hemophilia A

by Zacks Equity Research

Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.

Zacks Equity Research

Align (ALGN) Hurt by Dental Practice Closures, FX Headwind

by Zacks Equity Research

Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.

Zacks Equity Research

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Zacks Equity Research

CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout

by Zacks Equity Research

CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.

Zacks Equity Research

Humana (HUM) to Offer Home Care Model to Virginia's MA Members

by Zacks Equity Research

Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.

Zacks Equity Research

Here's Why Investors Should Retain Chemed (CHE) Stock Now

by Zacks Equity Research

Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.

Zacks Equity Research

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.

Zacks Equity Research

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

Zacks Equity Research

AMN Healthcare Services (AMN) Stock Moves -0.41%: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $100.27 in the latest trading session, marking a -0.41% move from the prior day.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) for Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) strong organic sales and notable acquisitions.

Zacks Equity Research

AMN or PGNY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. PGNY: Which Stock Is the Better Value Option?

Zacks Equity Research

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

by Zacks Equity Research

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

Zacks Equity Research

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

by Zacks Equity Research

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.

Zacks Equity Research

Veeva Systems (VEEV) Unveils New Study Training Application

by Zacks Equity Research

Veeva Systems' (VEEV) new clinical study training application will address the demands and complexities involved in present-day trials.

Zacks Equity Research

Here's Why Investors Should Retain Alcon (ALC) Stock For Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.

Zacks Equity Research

Thermo Fisher (TMO) to Promote Mass Spectrometry Imaging

by Zacks Equity Research

Thermo Fisher's (TMO) new deal with TransMIT will advance the use of the AP-SMALDI5 AF ion source with Orbitrap MS technology for spatial multi-omics applications.

Zacks Equity Research

Henry Schein (HSIC) Inks New Deal to Acquire Condor Dental

by Zacks Equity Research

Henry Schein's (HSIC) acquisition of a Switzerland-based dental distribution company will strengthen its presence in the attractive European market.

Zacks Equity Research

Viatris (VTRS) Up 13.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Anthem (ANTM) Ties Up to Improve Maternal Health Outcomes

by Zacks Equity Research

Anthem (ANTM) teams up with Happify Health to bring a digital-first solution aimed at addressing issues stemming from the pregnancy experience and other health aspects of women.

Zacks Equity Research

PerkinElmer (PKI) Unveils New NGS System to Aid Genomic Analysis

by Zacks Equity Research

PerkinElmer's (PKI) introduction of the RUO BioQule NGS System is a cost-effective system that can bring improvements in genomic analysis.